Genmab — Marts 2018
-
Blood journal article - “Dar”-ing to target CD38 in T-ALL - http://www.bloodjournal.org/content/131/9/948?sso-checked=true
-
I imagine this goes with this abstract we saw earlier in the year -
http://www.bloodjournal.org/content/early/2018/01/04/blood-2017-07-794214?sso-checked=true -
Morn
here mere af samme skuffe som diskuteret igaar. https://www.ncbi.nlm.nih.gov/labs/pubmed/29500635-daratumumab-augments-alloreactive-natural-killer-cell-cytotoxicity-towards-cd38-multiple-myeloma-cell-lines-in-a-biochemical-context-mimicking-tumour-microenvironment-conditions/?from_term=Myeloma+Cells+&from_sort=date&from_pos=5 -
-
God morgen.
-
God morgen
-
Det ser umiddelbart ud til at blive en god dag på markederne.
-
Jeg skød mine bulls i dag med et lille plus samlignet med hvis jeg havde købt aktien istedet.
Har købt normale genmab aktier istedet. -
Jeg tror ikke, at 1250 er en speciel stærk modstand. Vi er bare i en situation, hvor både købere og sælgere sidder tålmodigt på gærdet.
-
Vi kan i hvert fald konstatere, at der ikke er noget tegn på lukning af det store gap der opstod efter den nylige store stigning.
-
Det hele ser pt. meget normalt og sundt ud efter min ydmyge mening.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind